Sleep duration, chronotype, and lifestyle affect cognitive decline

FHS
July 15, 2024
9:12 am

Researchers explore the impact of lifestyle and health conditions on the prevalence and incidence of cognitive decline.

Semaglutide shows significant kidney benefits in non-diabetic obese patients with heart disease

A recent study in Nature Medicine shows semaglutide reduces kidney risks in non-diabetic obese patients with cardiovascular disease by 22%. The SELECT trial results highlight

May 29, 2024

Marinus reports mixed Phase 3 results on IV seizure drug

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

June 18, 2024

Will WHO’s new guidance spur hepatitis B immunisation? – Pharmaceutical Technology

Image credit: Shutterstock/chemical industry Despite vaccine developments signalling advancements in the diagnosis, prevention and treatment of hepatitis B, the World Health Organization’s (WHO) 2024 Global

June 21, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.